Jazz Pharmaceuticals achieved record revenues of over $1.1 billion in Q3 2025, fueled by strong sales across its product portfolio and two significant FDA approvals, paving the way for continued growth and strategic advancements.

• Secured FDA approvals for Modeyso and Zepzelca, expanding treatment options for severe conditions.
• Strong commercial performance driven by Xywav's 11% year-over-year growth, contributing $431 million in net sales.
• Narrowed 2025 revenue guidance to $4.175 billion - $4.275 billion, reflecting confidence in future performance.
• Completed settlements in Xyrem antitrust litigation, allowing focus on strategic execution and shareholder value.
• Strengthened the pipeline with the Saniona licensing agreement for a promising epilepsy candidate, SAN2355.